HOUSE_OVERSIGHT_024823.jpg
1.24 MB
Extraction Summary
15
People
4
Organizations
2
Locations
0
Events
1
Relationships
3
Quotes
Document Information
Type:
Financial research report / market analysis
File Size:
1.24 MB
Summary
This document is page 7 of a financial research report titled 'Cowen's Collective View of CBD,' dated February 25, 2019. It outlines the anticipated growth of the U.S. CBD market to $16 billion by 2025 and lists various analysts covering specific sectors such as consumer products, pharmacy, and regulation. The document bears a 'HOUSE_OVERSIGHT' stamp, indicating it was likely produced as part of a congressional investigation, possibly related to banking records, though the text itself contains no direct references to Jeffrey Epstein.
People (15)
| Name | Role | Context |
|---|---|---|
| Michael Cella | Recipient/Employee |
Listed in the watermark as the intended recipient: michael.cella@cowen.com
|
| Azer | Analyst |
Author of sections on Market Sizing, Opportunities, Competitive Landscape, and Global Landscape
|
| Nadeau | Analyst |
Author of sections on Science of CBD and Pharmaceutical Applications
|
| Neivert | Analyst |
Co-author of Supply Chain section
|
| Schenkel | Analyst |
Co-author of Supply Chain section
|
| Rhyee | Analyst |
Author of Pharmacy section
|
| Blackledge | Analyst |
Author of E-Commerce section
|
| Chen | Analyst |
Author of Broader Retail section
|
| Kernan | Analyst |
Author of Specialty Brands section
|
| Charles | Analyst |
Author of On-Premise Consumption Opportunities section
|
| Assaraf | Analyst |
Co-author of U.S. Regulatory Outlook
|
| Krueger | Analyst |
Co-author of U.S. Regulatory Outlook
|
| Seiberg | Analyst |
Co-author of U.S. Regulatory Outlook
|
| Weissenstein | Analyst |
Co-author of U.S. Regulatory Outlook
|
| Osborne | Analyst |
Author of Industrial Applications section
|
Organizations (4)
| Name | Type | Context |
|---|---|---|
| Cowen |
Financial services firm publishing the report
|
|
| GWPharma |
Mentioned as proving efficacy for seizures with Epidiolex
|
|
| WEED |
Cited as considering spending $500mm in U.S. hemp/CBD
|
|
| House Oversight Committee |
Implied by the footer stamp 'HOUSE_OVERSIGHT_024823'
|
Relationships (1)
Sidebar text: 'This report is intended for michael.cella@cowen.com'
Key Quotes (3)
"By 2025, we estimate that the U.S. CBD market could approach $16 bn (from $600 mm -$2 bn in 2018)."Source
HOUSE_OVERSIGHT_024823.jpg
Quote #1
"Indeed, our consumer survey work suggest that close to 7% of adults in the U.S. already use CBD as a supplement."Source
HOUSE_OVERSIGHT_024823.jpg
Quote #2
"WEED announced that they would consider spending as much as $500 mm in U.S. hemp / CBD"Source
HOUSE_OVERSIGHT_024823.jpg
Quote #3
Full Extracted Text
Complete text extracted from the document (2,067 characters)
COWEN
COLLABORATIVE INSIGHTS
February 25, 2019
COLLABORATIVE INSIGHTS
February 25, 2019
COWEN’S COLLECTIVE VIEW OF CBD
In a collaboration featuring 11 analysts across Cowen’s consumer, health care,
industrials and regulatory teams, herein we offer our outlook for the global CBD market,
with a particular focus on the U.S. While little science exists supporting medical efficacy
of CBD (with the exception of seizures, which GWPharma was able to prove with
Epidiolex for Dravet syndrome and Lennox-Gastaut syndrome, as discussed in more
detail herein), the popularity of CBD products seems to be growing exponentially in the
U.S. Indeed, our consumer survey work suggest that close to 7% of adults in the U.S.
already use CBD as a supplement.
industrials and regulatory teams, herein we offer our outlook for the global CBD market,
with a particular focus on the U.S. While little science exists supporting medical efficacy
of CBD (with the exception of seizures, which GWPharma was able to prove with
Epidiolex for Dravet syndrome and Lennox-Gastaut syndrome, as discussed in more
detail herein), the popularity of CBD products seems to be growing exponentially in the
U.S. Indeed, our consumer survey work suggest that close to 7% of adults in the U.S.
already use CBD as a supplement.
With the category gaining increasing interest from consumers we have seen a swell in
product innovation. And, the opportunity is increasingly drawing the attention of larger
competitors (where for instance, WEED announced that they would consider spending
as much as $500 mm in U.S. hemp / CBD). By 2025, we estimate that the U.S. CBD
market could approach $16 bn (from $600 mm -$2 bn in 2018).
product innovation. And, the opportunity is increasingly drawing the attention of larger
competitors (where for instance, WEED announced that they would consider spending
as much as $500 mm in U.S. hemp / CBD). By 2025, we estimate that the U.S. CBD
market could approach $16 bn (from $600 mm -$2 bn in 2018).
Herein, we offer our views of:
1. Consumer Products Market Sizing (Azer)
2. The Science of CBD (Nadeau)
3. The Hemp / CBD Supply Chain: From Cultivation to Extraction (Neivert & Schenkel)
4. Consumer Products Opportunities (Azer)
5. The CBD Competitive Landscape - Public and Private Company Discussions (Azer)
6. Consumer Discretionary Retail and Brand Opportunities Across:
a. Pharmacy (Rhyee)
b. E-Commerce (Blackledge)
c. Broader Retail (Chen)
d. Specialty Brands (Kernan)
a. Pharmacy (Rhyee)
b. E-Commerce (Blackledge)
c. Broader Retail (Chen)
d. Specialty Brands (Kernan)
7. On-Premise Consumption Opportunities (Charles)
8. U.S. Regulatory Outlook (Assaraf, Krueger, Seiberg & Weissenstein)
9. Global CBD Landscape (Azer)
10. Additional Potential Opportunities for Hemp / CBD, Including
a. Pharmaceutical Applications (Nadeau)
b. Industrial Applications (Osborne)
a. Pharmaceutical Applications (Nadeau)
b. Industrial Applications (Osborne)
[Sidebar Text]
This report is intended for michael.cella@cowen.com. Unauthorized redistribution of this report is prohibited.
This report is intended for michael.cella@cowen.com. Unauthorized redistribution of this report is prohibited.
COWEN.COM
7
HOUSE_OVERSIGHT_024823
7
HOUSE_OVERSIGHT_024823
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein document